Continuum
Innovative
Life Sciences Division

Intellectual Property

Three Decades ofSustained Innovation

Intellectual property is the visible record of an evolving scientific platform. Read from top to bottom, the timeline below traces the program's continuous trajectory — from early follicular biology and the founding HairGenesis® formulation, through global commercialization and category-defining peer-reviewed milestones, into the current Continuum platform and its active USPTO provisional portfolio.

Platform Evolution

  1. Era IEarly 1990s — 2002

    Foundational follicular biology

    Early work in follicular pharmacology and the formulation chemistry that would become HairGenesis® — culminating in the first randomized, double-blind, placebo-controlled clinical trial of botanical 5α-reductase inhibition in androgenetic alopecia.

    • platform

      HairGenesis® — founding formulation platform

    • publication

      Prager, Bickett, French, Marcovici — JACM 8(2):143–152

      2002 · First-in-field Level-1 evidence

  2. Era II2003 — 2011

    Inflammatory reframing of AGA

    Genome-wide transcriptomic work in keratinocytes — in collaboration with the SUNY Center for Functional Genomics — reframed androgenetic alopecia as a partly inflammatory disease and introduced multi-target, anti-inflammatory follicular therapy to the peer-reviewed record.

    • publication

      Chittur, Parr, Marcovici — Evid. Based Complement. Alt. Med.

      2011 · Whole-genome anti-inflammatory dataset

  3. Era III2013 — 2018

    Global commercialization & comparator biology

    Worldwide commercialization of HairGenesis® through Monrone as the program's primary GCC commercialization partner — combined with parallel bench work showing that a defined multi-component botanical composition could outperform finasteride on androgen-axis biomarkers in matched dermal-papilla and LNCaP assays.

    • platform

      Monrone — primary GCC commercialization partner

    • publication

      Marcovici et al. — Phytotherapy Research (Wiley)

      2016 · Outperformed finasteride at the bench

  4. Era IV2019 — 2022

    Nano-delivery & TrichoCyte™ platform

    Translation of the program into a β-cyclodextrin inclusion-complex nano-delivery architecture — published as a clinical case series and protected as proprietary platform chemistry that has since seen broad category emulation under generic 'nano-encapsulated' marketing language.

    • platform

      TrichoCyte™ — nano-inclusion delivery platform

    • publication

      Marcovici & Bauman — Cosmetics 7(3):65

      2020 · First clinical use of β-cyclodextrin inclusion delivery in AGA

  5. Era V2023 — present

    Continuum platform · current IP portfolio

    The current Continuum Innovative platform — a unified, hypothesis-driven framework spanning intracrine regulation, immune privilege, multi-nodal stability, senescence biology, and menopause-associated follicular destabilization. Seven filed USPTO provisional patent applications anchor the portfolio; a cryo-CO₂ amplification approach is the subject of ongoing collaborative exploration.

Active USPTO Provisional Portfolio

Seven filed USPTO provisional patent applications protecting the current Continuum platform.

Select a program below to open its illustrated deep-dive.

01

Progressive Autoimmune Loss of Privilege

USPTO Provisional

64/065,059

  • Immune privilege
  • Follicular territorial integrity
  • Antigen suppression
02

Intracrine Structure–Function Dynamics

USPTO Provisional

64/063,263

  • Intracrine regulation
  • Local androgen metabolism
  • Pleiotropic signaling
03

Coordinated Multi-Nodal Stabilization

USPTO Provisional

64/069,570

  • Multi-nodal stabilization
  • Phenotype architecture
  • Integrated signaling
04

Senescence Biology

USPTO Provisional

64/073,264

  • Cellular senescence
  • Regenerative competence
  • Follicular aging
05

Menopause-Associated Follicular Destabilization

USPTO Provisional

64/095,147

  • Menopausal transition
  • Endocrine-follicular axis
  • Destabilization reversal
06

Follicle–Stromal Field Biology

USPTO Provisional · Filing 06

64/136,221

Filed August 18, 2026

“SPATIALLY ORGANIZED TISSUE-FIELD REGULATION OF ANDROGENETIC ALOPECIA SUSCEPTIBILITY, PHENOTYPE EXPRESSION, AND PROGRESSION”

  • Stromal microenvironment
  • Follicle–stroma signaling
  • Field stabilization
07

Convergent Privilege Collapse

USPTO Provisional · Filing 07

64/156,448

Filed September 16, 2026

“SYSTEMS AND METHODS BASED ON CONVERGENT PRIVILEGE COLLAPSE FOR CHARACTERIZING AND MODULATING TISSUE DYSFUNCTION”

  • Multi-compartment barrier failure
  • Containment restoration
  • Regenerative competence recovery

Filing 07 · USPTO Provisional 64/156,448 · Filed September 16, 2026

Convergent Privilege Collapse

USPTO-filed title: “SYSTEMS AND METHODS BASED ON CONVERGENT PRIVILEGE COLLAPSE FOR CHARACTERIZING AND MODULATING TISSUE DYSFUNCTION”

Continuum Innovative has filed a provisional patent application covering Convergent Privilege Collapse (CPC), a unifying framework for understanding how age-associated and chronic tissue dysfunction may emerge when multiple normally protected biological compartments fail together. These protective systems include structural barriers, immune privilege, genomic and mitochondrial containment, extracellular-matrix organization, and regenerative stem-cell niches.

CPC proposes that once these safeguards deteriorate beyond a critical threshold, normally sequestered or silenced biological material may become aberrantly exposed, triggering inflammatory sensing, antigen presentation, cellular senescence, fibrosis, pathological tissue remodeling, and progressive loss of regenerative function.

The application describes methods for identifying CPC through same-patient comparisons of protected and phenotype-affected tissue, integrating molecular, spatial, and functional measurements into composite indices. It further establishes a framework for selecting multi-target interventions designed to restore biological containment, interrupt self-reinforcing pathological signaling, normalize tissue architecture, and recover regenerative competence.

Hair-follicle miniaturization and age-associated hair loss represent principal applications, while the broader CPC architecture may extend across multiple inflammatory, fibrotic, degenerative, and age-related conditions.

The seven application numbers identify filed USPTO provisional patent applications. Nonpublic claim strategy and prosecution materials remain subject to appropriate confidentiality.

Contact